Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all
Completed Phase 3 Interventional

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

NCT00765700
View directory record Official record
Conditions
Sprain, Strain, Acute Soft Tissue Injury
Interventions
Topical Ketoprofen 10% Cream, Topical Placebo Cream
Drug
Lead sponsor
Imprimis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 25, 2026, 3:34 AM EDT
Recruiting Phase 2 Interventional

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

NCT07620392
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
5
States / cities
Tamarac, Florida • Lake Charles, Louisiana • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

NCT01513902
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 25, 2026, 3:34 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
JNJ-88545223, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Not applicable Interventional

Exercise and Body Composition in Juvenile Idiopathic Arthritis

NCT02479373
View directory record Official record
Conditions
Arthritis, Juvenile
Interventions
Ren-Ex Machine, Dual-Emission X-ray Absorptiometry (DEXA) scan, Biodex dynamometer, Sub-maximal test, Quality of life questionnaires
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis Participants

NCT01721057
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
48
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 25, 2026, 3:34 AM EDT
Completed No phase listed Observational

Research Participants' Views on the Ethics of Clinical Research

NCT00457041
View directory record Official record
Conditions
Rheumatic Diseases
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sonographic Features of Normal Soft Tissues of the Feet

NCT00719004
View directory record Official record
Conditions
Foot Disease, Healthy
Interventions
Ultrasound of the foot
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 25, 2026, 3:34 AM EDT
Completed No phase listed Observational

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

NCT00565526
View directory record Official record
Conditions
Sjogren's Syndrome, Dysautonomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

NCT02990806
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
NI-071, Remicade
Drug
Lead sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
75
States / cities
Little Rock, Arkansas • Los Angeles, California • Ventura, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 1 Interventional

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

NCT00550355
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PD 0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Peoria, Arizona • Daytona Beach, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

NCT03529955
View directory record Official record
Conditions
Dermatomyositis, Adult Type
Interventions
Apremilast 30mg
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790
View directory record Official record
Conditions
Rheumatoid Arthritis, Renal Impairment
Interventions
fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 25, 2026, 3:34 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

NCT04035668
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

NCT02332590
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Covina, California • Long Beach, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Adalimumab, CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
22
States / cities
Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

NCT00034060
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 3:34 AM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

NCT02843659
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
BMS-931699, BMS-986142, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Fullerton, California • Palo Alto, California • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

NCT00299546
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 25, 2026, 3:34 AM EDT
Completed Phase 1 Interventional

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

NCT04911127
View directory record Official record
Conditions
Rheumatoid Arthritis, Cannabis
Interventions
200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily, Placebo capsules
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 25, 2026, 3:34 AM EDT